WIRB-Copernicus Group (WCG), one of the world’s leading providers of solutions that measurably improve the quality and efficiency of clinical research, has announced that Clintrax Global has joined its family of companies.
Founded by former biopharmaceutical and clinical research organization (CRO) attorneys, Clintrax Global provides outsourced services for negotiating clinical trial-related contracts and budgets between biopharmaceutical companies, CROs and investigator sites around the world. Clintrax Global also manages, executes and tracks payments between these global clinical trial participants.
“WCG’s solutions help biopharmaceutical companies reduce the time, cost and risks associated with bringing new therapies to market, while ensuring the highest quality of human subject protection,” commented WCG Chairman and Chief Executive Officer (CEO) Donald A. Deieso, PhD. “Our biopharmaceutical and institutional clients continue to cite — among the top impediments to clinical trial activation — the delays associated with negotiating study budgets and contracts. By adding Clintrax Global to the WCG family of companies, we can now offer them a more comprehensive and integrated suite of study start-up solutions.”
Since its inception, Clintrax Global has accelerated hundreds of clinical trials conducted in more than 65 countries. Comprising a team of more than 60 attorneys located around the world, Clintrax Global’s experts possess specialized and in-depth knowledge of local languages and regulations, and have established relationships with the leading clinical research sites in those countries.
In addition to an expert team, Clintrax Global has developed an efficient technology driven process that enables the expedited management of negotiations. As a result, the amount of time devoted to the negotiating process — from start to finish — is significantly reduced.
“Our team is excited to join the WCG family, and to become part of a dedicated organization that works tirelessly to create a more efficient way to conduct clinical trials,” said Clintrax Global CEO Brandon Evans. “We are confident that — as part of the WCG family — we will have the opportunity to impact global health on an even greater scale.”
Clintrax Global will continue to operate as an independent company and its headquarters will remain in Raleigh, North Carolina, USA. Financial details about the transaction were not disclosed.